Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 3/20 | 0.56 |
| ▸ | APAF1 | O14727 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5996640 | 0.91 | TDP1 (0.68) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL6844173 | 0.90 | TDP1 (0.64) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL5993924 | 0.90 | TDP1 (0.64) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL5105288 | 0.87 | TDP1 (0.76) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL27458266 | 0.87 | TDP1 (0.76) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL5099431 | 0.87 | TDP1 (0.76) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL5096480 | 0.87 | TDP1 (0.76) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL5096575 | 0.82 | TDP1 (0.77) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL2325907 | 0.81 | TDP1 (0.92) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL16072816 | 0.80 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2006-10-05 | — | — | US | disclosed |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2004-07-08 | — | — | US | disclosed |
| US-6693095-B2 | 7-(((5-AMINO-1,2,4-THIADIAZOL-3-YL)-(Z)-(FLUORMETHOXYIMINO) -ACETYL)AMINO)-3(E)-((IMINO-1-PIPERAZINYLMETHYL)-METHYLHYDRAZONO)METHYL-3 -CEPHEM-4-CARBOXYLIC ACID TRIHYDROCHLORIDE FOR EXAMPLE | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2004-02-17 | — | — | US | disclosed |
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2003-06-19 | — | — | US | disclosed |
| EP-1300408-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono)methyl-cephalosporins and intermediates | BIOCHEMIE Gesellschaft m.b.H. (AT) | 2003-04-09 | — | — | EP | disclosed |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | ASCHER GERD (AT) | 2002-08-22 | — | — | US | disclosed |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | NABRIVA THERAPEUTICS AG (AT) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114665-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TDP1 4748/4885MAPT 4782/4885ABCC4 1260/4885 |
| US-20020115852-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TDP1 4748/4885MAPT 4782/4885ABCC4 1260/4885 |
| US-20020091252-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TDP1 4748/4885MAPT 4782/4885ABCC4 1260/4885 |
| US-20060223789-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, PRMT7 | TDP1 4852/4885MAPT 4713/4885ABCC4 1569/4885 |
| US-20040132709-A1 | Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates | MRPL21, Q6ZSR9, EMG1 | TDP1 4748/4885MAPT 4782/4885ABCC4 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.